Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).

Citation

• Karapetis, C. S., Clingan, P. R., Leighl, N. B., Durbin-Johnson, B., O'Neill, V., & Spigel, D. R. (2010). Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 28(15_suppl), 7535. doi:10.1200/jco.2010.28.15_suppl.7535

Digital Object Identifier (doi)

• 10.1200/jco.2010.28.15_suppl.7535

Web Of Science Accession Number

Start Page

• 7535

End Page

• 7535

Volume

• 28

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   Clingan, Phillip (external author)

Publication Date

• 2010

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Karapetis, C. S., Clingan, P. R., Leighl, N. B., Durbin-Johnson, B., O'Neill, V., & Spigel, D. R. (2010). Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 28(15_suppl), 7535. doi:10.1200/jco.2010.28.15_suppl.7535

Digital Object Identifier (doi)

• 10.1200/jco.2010.28.15_suppl.7535

Web Of Science Accession Number

Start Page

• 7535

End Page

• 7535

Volume

• 28

Issue

• 15_suppl

Place Of Publication